Differential transcriptional regulation of hypoxia-inducible factor-1α by arsenite under normoxia and hypoxia: involvement of Nrf2

Zukaa al Taleb 1 · Andreas Petry 2,3 · Tabughang Franklin Chi 1 · Daniela Mennerich 1 · Agnes Görlach 2,3 · Elitsa Y. Dimova 1 · Thomas Kietzmann 1

Received: 2 February 2016 / Revised: 31 May 2016 / Accepted: 3 June 2016 / Published online: 10 June 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract
Arsenite (As(III)) is widely distributed in nature and can be found in water, food, and air. There is significant evidence that exposure to As(III) is associated with human cancers originated from liver, lung, skin, bladder, kidney, and prostate. Hypoxia plays a role in tumor growth and aggressiveness; adaptation to it is, at least to a large extent, mediated by hypoxia-inducible factor-1α (HIF-1α). In the current study, we investigated As(III) effects on HIF-1α under normoxia and hypoxia in the hepatoma cell line HepG2. We found that As(III) increased HIF-1α protein levels under normoxia while the hypoxia-mediated induction of HIF1α was reduced. Thereby, the As(III) effects on HIF-1α were dependent on both, transcriptional regulation via the transcription factor Nrf2 mediated by NOX4, PI3K/Akt, and ERK1/2 as well as by modulation of HIF-1α protein stability. In line, the different effects of As(III) via participation of HIF-1α and Nrf2 were also seen in tube formation assays with endothelial cells where knockdown of Nrf2 and HIF-1α abolished As(III) effects. Overall, the present study shows that As(III) is a potent inducer of HIF-1α under normoxia but not under hypoxia which may explain, in part, its carcinogenic as well as anti-carcinogenic actions.

Key message
- As(III) increased HIF-1α under normoxia but reduced its hypoxia-dependent induction.
- The As(III) effects on HIF-1α were dependent on ROS, NOX4, PI3K/Akt, and ERK1/2.
- The As(III) effects under normoxia involved transcriptional regulation via Nrf2.
- Knockdown of Nrf2 and HIF-1α abolished As(III) effects in tube formation assays.
- The data may partially explain As(III)’s carcinogenic and anti-carcinogenic actions.

Keywords Hypoxia-inducible factor 1 (HIF-1α) · Arsenite As(III) · Mitogen-activated protein kinase (MAPK) · Reactive oxygen species (ROS) · NADPH enzyme oxidase 4 (NOX4)

Introduction
Several regions in Argentina, Canada, India, Japan, China, Taiwan, Mexico, Chile, and the USA are characterized by the presence of inorganic arsenic as natural contaminant in drinking water. This implies that more than 100 million persons are chronically exposed to inorganic arsenic at levels higher than the maximum contaminant level of 0.13 μmol/l set by the WHO [1].

It is long known that chronic arsenic inhalation or ingestion is toxic and causes a number of health problems. Although the clinical manifestations of arsenic toxicity vary widely between persons and populations, chronic exposure to arsenic is, if not causing death, associated with a
greater risk of ischemic heart disease [2], neurologic consequences [3] in adults and children [4] as well as with the appearance of cancer [5] in the lung, skin, kidney, bladder, and liver [6].

Solid tumors are characterized by the occurrence of areas with limited oxygen supply and it was shown that cells present in the hypoxic areas contain high levels of the hypoxia-inducible factor-1 alpha protein (HIF-1α) (for review, see [7]). The HIF-1α protein forms, together with its heterodimeric partner HIF-1β or ARNT, the proper transcription factor hypoxia-inducible factor-1 (HIF-1) which has been found to be critical for the regulation of more than 100 genes in response to hypoxia. A prerequisite for the formation of the HIF-1 heterodimer is the hypoxia-dependent stabilization of the HIF-1α subunit and the recruitment of coactivators. This is primarily achieved at the post-translational level by hydroxylation events occurring at the N-terminal (N-TAD) and C-terminal (C-TAD) transactivation domain of HIF-1α [7–9]. Further, phosphorylation events [10–12] and mechanisms leading to enhanced HIF-1α gene transcription [13] also contribute to an increase in HIF-1α protein levels. In addition to hypoxia, HIF-1α is also responsive to a variety of non-hypoxic stimuli among them transition metals such as CoCl2, chromium, or arsenite (for review, see [14, 15]).

Although arsenite seems to exert some of its effects through direct interaction of the trivalent arsenite anion (AsO3³⁻) with the thiol groups of vicinal cysteines in target proteins [16, 17], the underlying mechanisms by which arsenic contributes to HIF-1α activation and carcinogenesis are rather controversial [18–20] and thus remain largely unknown. In particular, the effects of arsenite on the regulation of HIF-1α under tumor-promoting conditions like hypoxia have never been explored. In order to gain a better understanding about the mechanisms and actions involved when cells are exposed to arsenite, we focused in the current study on the impact of arsenite on HIF-1α regulation under normoxia and hypoxia.

We found that arsenite induced the levels of HIF-1α under normoxia via a transcriptional mechanism involving NADPH oxidase-generated reactive oxygen species (ROS), the PI3K/Akt and ERK1/2 pathway, and the redox-dependent transcription factor Nrf2. Moreover, arsenite was able to induce DNA synthesis and angiogenesis in a Nrf2- and HIF-1α-dependent manner. By contrast, arsenite reduced the hypoxia-dependent upregulation of HIF-1α, though increasing its stability. Together, the current findings indicate that arsenite may act as a powerful modulator of the HIF system with different effects under normoxia and hypoxia which may explain, in part, its ambivalent role in cancer and its potential therapeutic use.

Materials and methods

All biochemicals and enzymes were of analytical grade and purchased from commercial suppliers. Sodium arsenite (As(III)), actinomycin D (ActD), and cycloheximide (CHX) were purchased from Sigma. The specific inhibitors for the mitogen-activated protein kinase (MEK) U0126 and PD98059, the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, Jun N-terminal kinase (JNK) inhibitor SP600125, and the p38 protein kinase inhibitor SB202190 were purchased from Enzo, Roche Diagnostics GmbH (Mannheim).

Cell culture and cell treatment

Human hepatoma HepG2 cells were cultured in a normoxic atmosphere at 16 % O2, 79 % N2, and 5 % CO2 (by volume) in Earle’s minimal essential medium supplemented with 10 % fetal calf serum (FCS) for 24 h. At 24 h, the medium was changed and the culture was continued under normoxic conditions at 16 % O2 or hypoxic conditions at 5 % O2 (with 90 % N2 and 5 % CO2 [by volume]).

Human microvascular endothelial cells (HMEC-1) were cultured under the same atmospheres in MCDB131 medium (Gibco) supplemented with 10 % FCS. Nrf2 knockdown mouse embryonic fibroblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10 % fetal calf serum and were a kind gift from S. Immenschuh.

For treatment of cells with As(III), cells were cultured in 60 mm diameter dishes and grown overnight. Thereafter, As(III) was added to the media, and cells were further incubated for the time periods indicated. None of the used As(III) concentrations exerted unspecific cell damage or toxicity as assessed by LDH leakage (data not shown). Pre-treatment of cells with kinase inhibitors, ActD, and CHX was performed for 30 min, respectively, prior to the addition of As(III).

Plasmid constructs

The reporter constructs for pGL3-EPO-HRE [21], p(ARE)-p44-Luc [22], as well as siSTRIKE™ U6 shRNA Nrf2, siSTRIKE™ U6 shRNA HIF-1α plasmids, siSTRIKE™ U6 shNOX4 were described previously [23, 24].

RNA preparation and Northern blot analysis

The isolation of total RNA and Northern blot analysis were performed as described previously [21]. Digoxigenin-labeled antisense RNAs hybridization probes were generated by in vitro transcription from pBS-Actin by using T7 polymerase or from pCRII-HIF-1α and pBS-HO-1 by using T7 polymerase. Blots were quantified with a video densitometer (Biotech Fischer, Reiskirchen, Germany).
Western blot analysis

Western blot analysis was carried out as described previously [21]. In brief, 100 µg of protein from medium or total lysates from HepG2 cells was subjected to Western blotting with monoclonal antibodies against PAI-1 (1:100; American Diagnostics, Pfungstadt, Germany), HIF-1α (1:1000; BD Biosciences, Heidelberg, Germany), phospho p42/p44 MAPK (1:1000), phospho p38 MAPK (1:1000), phospho Akt-T308 (1:1000) and phospho c-Jun-Ser73 (1:1000 (Cell Signaling) or rabbit polyclonal antibodies against HO-1 (1:1000; Cell Signaling, Biomol, Hamburg), Golgi membrane (58-kD cis-Golgi protein formiminotransferase cyclodeaminase) (1:10,000; Biosciences, Goettingen, Germany), or α-tubulin (1:10, 000; Sigma). The enhanced chemiluminescence (ECL) system was used for detection (Amersham Biosciences).

Cell transfection and luciferase assay

About 4 × 10^5 HepG2 cells per 60 mm diameter dish were transfected as described previously [11, 22]. In brief, cells were transfected with 2 µg pGL3-EPO-HRE or p(ARE)-p44-Luc, together with 0.25 µg of a Renilla luciferase expression construct (pRLSV40) (Promega, Heidelberg, Germany) to control transfection efficiency. The detection of luciferase activity was performed with a luciferase assay kit (Berthold, Pforzheim, Germany).

For knockdown experiments, cells were transfected with 10 µg of the respective psiSTRIKE shRNA plasmids overnight. The next day, the medium was changed and cells were treated as described above.

Protein half-life

Protein half-life studies were performed in HepG2 cells treated with 50 µM As(III) under normoxia and hypoxia for 4 h. After 4 h, cycloheximide (100 µg/ml) was added to the medium for different times and cells were further cultured under normoxia and hypoxia. After harvesting the cells, endogenous HIF-1α protein levels were measured by immunoblot analysis.

Measurement of ROS

Measuring ROS was performed by using the non-fluorescent dye dichlorodihydrofluorescein diacetate (H2DCFDA). Fluorescence measurements were performed in six-well plates (10,000 cells/well). The cells were treated with 50 µM As(III) and after 4 h the cells were washed with 1× PBS and 10 µM H2DCFDA was added for 20 min at 37 °C in dark. DCF fluorescence in each well was measured with a Fluoroscan fluorescence plate reader at 37 °C at an excitation wavelength of 488 nm and an emission wavelength of 538 nm. In addition, ROS measurements were performed by electron paramagnetic resonance (EPR) using the spin probe 1-hydroxymethoxy carbonyl-2,2,5,5-tetramethylpyrrolidine hydrochloride (CMH, Noxygen, Elzach, Germany). Briefly, cells were treated with As(III) in the presence or absence of hypoxia (5 % O2) for 4 h. Cells were washed once in 1× PBS, harvested in Krebs-Hepes buffer and supplemented with 5 µM diethylthiocarbamate, 25 µM desferrioxamine, and 100 µM CMH under normoxic or hypoxic conditions. Cell suspensions were placed in air-tight glass capillaries and spectra were recorded in an EPR spectrometer with temperature-controlled resonator (e-scan, Noxygen). EPR settings for CMH spin label were as follows: center field 3455 G, sweep width 10 G, frequency 9.7690 GHz, microwave power 23.89 mW, and modulation amplitude 2.93 G. Spectra were recorded over 10 min.

BrdU cell proliferation and colony formation assay

HepG2 cells transfected with plasmids expressing control scrambled shRNA or shRNA against HIF-1α or Nrf2 were cultured with or without As(III) in 96-well plates for 4 h. The bromodesoxyuridine (BrdU) assay (Calbiochem) was performed according to the manufacturer’s instructions and the absorbance was measured at dual wavelengths of 450 and 540 nm.

Colony formation was assessed in a Hep3B monolayer assay by seeding cells at different densities (500–3000 cells/well in steps of 500) in six-well plates and growing them for 4 days. Afterwards, cells were fixed and stained with crystal violet counted and quantified.

In vitro matrigel angiogenesis assay

HMEC-1 cells were transfected with expression vectors for shHIF-1α, shNrf2, or with the respective control vectors. Cells were seeded at a density of 50,000 cells/well on a 96-well plate mounted with growth factor reduced Matrigel (BD Biosciences). The cells were allowed to settle for 2 h in normoxia and were then cultured where indicated in the presence of As(III). After incubation, the cells were stained with the fluorescent dye Calcein AM (Mobitec, Germany). The formation of capillary-like structures was assessed by light microscopy and quantified using Image J software (Wright Cell Imaging Facility, Toronto, Canada).

Statistical analysis

Densitometry data were plotted as fold induction of relative density units, with the zero value absorbance in each figure set arbitrarily to 1 or 100 %. Statistical comparisons of absorbance differences were performed by the Mann-Whitney test.
(Statview 4.5, Abacus Concepts, Berkeley, CA), and p values
\( p \leq 0.05 \) were considered significant. Values presented are
means ± SEM. Results were compared by ANOVA for repeated
Luc measurements followed by the Newman-Keuls test. A
probability level \( p \leq 0.05 \) was accepted as significant.

Results

Arsenite induces HIF-1\(\alpha\) protein levels under normoxia
but reduces the effect of hypoxia

To examine the effect of As(III) on HIF-1\(\alpha\) protein levels
in HepG2 cells, different concentrations of As(III) were
first applied to the cells for 4 h under normoxia and
hypoxia. The western blot analyses revealed that treatment
of cells with As(III) at concentrations of 10, 50, and
100 \( \mu \)M induced HIF-1\(\alpha\) under normoxia (Fig. 1a, c); a
higher concentration of 300 \( \mu \)M As(III) did not exert an
effect on HIF-1\(\alpha\) under normoxia (Fig. 1a, c).

Interestingly, the inducing effect of As(III) on HIF-1\(\alpha\)
was lost when the As(III) treatment was performed under
hypoxia. While hypoxia alone exerted the strongest induc-
tion on HIF-1\(\alpha\) (about 4-fold), co-treatment with 10, 50,
100, and also 300 \( \mu \)M As(III) reduced the hypoxia-
dependent induction of HIF-1\(\alpha\) by about 20, 30, 50, and
100 %, respectively (Fig. 1a, c).

In addition, we determined a time course of the HIF-1\(\alpha\)
response towards As(III) under normoxia and hypoxia. The
western blot analyses showed that As(III) slightly induced
HIF-1\(\alpha\) protein levels already after 2 h under normoxia.
The induction increased and became maximal after 4 h; thereaf-
after HIF-1\(\alpha\) levels did not increase further. In addi-
tion, the results show that the hypoxia-dependent HIF-1\(\alpha\)
protein induction starts after 2 h; treatment with As(III) for
2 h and longer inhibited the hypoxia-dependent induction
of HIF-1\(\alpha\) (Fig. 1b, c). Together, these data indicate that
treatment of cells with As(III) induced HIF-1\(\alpha\) protein
levels under normoxia but reduced the hypoxia-dependent
HIF-1\(\alpha\) induction.

Arsenite regulates HIF-1\(\alpha\) at the transcriptional level

To gain insight into the mechanisms involved, we asked
whether As(III) regulates HIF-1\(\alpha\) via transcriptional mecha-
nisms. Initial experiments with the transcription inhibitor
actinomycin D supported the notion that As(III) affects
HIF-1\(\alpha\) transcription under normoxia and hypoxia (data
not shown). To further specify whether or not As(III) is able
to regulate HIF-1\(\alpha\) expression at the mRNA level, Northern
blot analyses were performed. Time course experiments
indicated that As(III) induced HIF-1\(\alpha\) mRNA levels by about
4-fold within 4 h of treatment under normoxia. However,

As(III) reduced HIF-1\(\alpha\) mRNA levels by about 50 % under
hypoxia (Fig. 2a, b). Together, these data provide the first
evidence that As(III) is able to regulate HIF-1\(\alpha\) at the tran-
scriptional level.

Fig. 1 Concentration- and time-dependent modulation of HIF-1\(\alpha\)
protein levels by As(III) under normoxia and hypoxia. Cells were
cultured under normoxia (16 % O\(\text{2}\)) for 24 h. After 24 h, the medium
was changed and cells were further cultured under normoxia and hypoxia
(5 % O\(\text{2}\)) and treated either with: a different concentrations of As(III) for
4 h; b 50 \( \mu \)M As(III) for the indicated time points. The HIF-1\(\alpha\) levels in
the absence of As(III) or in controls at 0 h were set to 1. Values represent
mean ± SEM of at least three independent experiments. Single asterisk,
significant difference control under normoxia vs. As(III); double
asterisks, significant difference control under hypoxia vs. As(III). c
Representative Western blot with 50 \( \mu \)M As(III) at 4 h. One hundred
micrograms of total protein was subjected to Western blot analysis with
an antibody against HIF-1\(\alpha\) or Golgi membrane (GM). Autoradiographic
signals were visualized by chemiluminescence and quantified by video
densitometry.
Arsenite induces HIF-1\(\alpha\) synthesis under normoxia and prolongs its half-life under hypoxia

To further analyze the mechanisms by which As(III) regulates HIF-1\(\alpha\) levels, we next examined whether ongoing protein synthesis or post-translational effects are involved. To do this, we first used cycloheximide (CHX) as translation inhibitor. Like in the previous experiments, As(III) induced HIF-1\(\alpha\) strongly under normoxia but reduced the hypoxia-dependent upregulation. When CHX was used, it completely abolished the induction of HIF-1\(\alpha\) by As(III) under normoxia but also the response towards hypoxia or combined treatment (Fig. 3a, b).

Since the above data indicated the involvement of protein synthesis in the regulation of HIF-1\(\alpha\) by As(III), we next asked whether this involves the rapamycin-sensitive mTORC1 complex. The mTORC1 activates translation via phosphorylation of p70-S6 Kinase-1 and the eukaryotic initiation factor 4E binding protein 1 (4E-BP1) which converge at the translation initiation complex at the 5’ end of the respective mRNA.

To test the participation of mTORC1 in the As(III)-mediated effects on HIF-1\(\alpha\), we used rapamycin as mTORC1 inhibitor. As before, treatment with As(III) under normoxia resulted in a strong upregulation of HIF-1\(\alpha\). Rapamycin reduced the As(III)-dependent HIF-1\(\alpha\) induction by about 50 % under normoxia but not under hypoxia (Fig. 3c, d).

These data support the notion that HIF-1\(\alpha\) induction by As(III) under normoxia involves mTORC1-regulated protein synthesis; however, they do not exclude that As(III) may affect HIF-1\(\alpha\) protein stability under hypoxia. Therefore, we also investigated whether As(III) has an effect on HIF-1\(\alpha\) protein stability. The half-life measurements indicated that the HIF-1\(\alpha\) half-life was about 20 min in As(III)-treated normoxic cells (Fig. 4a). As mentioned above, As(III) was found to reduce HIF-1\(\alpha\) protein induction under hypoxia; however, the half-life measurements showed that the HIF-1\(\alpha\) half-life after treatment with As(III) is prolonged in comparison to cells incubated only under hypoxia (Fig. 4c). Together, these data indicate that under normoxic conditions As(III) contributes to HIF-1\(\alpha\) regulation primarily via induction of transcription and translation whereas under hypoxia As(III) is able to stabilize HIF-1\(\alpha\).

As(III) induces HIF-1\(\alpha\) and the HIF-target genes PAI-1 and HO-1 via Nrf2

In a next step, we investigated the effect of As(III) on HIF transcriptional activity and the HIF-1\(\alpha\) target genes plasminogen activator inhibitor-1 (PAI-1) and heme oxygenase (HO-1). The results demonstrate that hypoxia, as shown earlier [25], induced PAI-1 expression by about 2.5-fold. As(III) treatment induced PAI-1 protein expression under normoxia by about 2-fold while it completely abrogated PAI-1 induction under hypoxia resembling the effects observed for HIF-1\(\alpha\) under these conditions (Fig. 5a, b). Similar to PAI-1 and HIF-1\(\alpha\) protein levels, we found that HIF activity was upregulated by about 3-fold under hypoxia while As(III) increased HIF activity by about 2.5-fold under normoxia and only by about 2-fold under hypoxia (Fig. 5c).

Further, HO-1 levels increased by about 2.5-fold in response to hypoxia, and by about 3.5 fold in response to As(III) under normoxia. Interestingly, the As(III) treatment under hypoxia increased HO-1 levels by 2.5-fold, similar to the situation with hypoxia alone (Fig. 5a, b). Thus, PAI-1 regulation followed the HIF-1\(\alpha\) regulation in response to As(III) under normoxia and hypoxia, whereas the response of HO-1 towards As(III) in particular under hypoxia did not entirely parallel the response to HIF-1\(\alpha\) suggesting an additional regulatory component.
Since HO-1 is also a bona fide target gene of the transcription factor Nrf2 (nuclear factor (erythroid-derived 2)-like 2) and well known to be responsive to As(III) [26], we also examined the response of Nrf2 towards hypoxia and As(III). Similar to HIF-1α, Nrf2 is regulated at the level of protein stability. In order to assess whether hypoxia and As(III) affect Nrf2 protein stability, we measured its half-life. In line with previous reports, we found that cellular Nrf2 is maintained at very low levels and that its half-life was about 15 min under both normoxia and hypoxia. Treatment of cells with As(III) extended the half-life of Nrf2 up to 30 min under normoxia and hypoxia (Fig. 4d–f).

Next we investigated whether hypoxia and As(III) influence Nrf2 activity. To do this, cells were transfected with a luciferase (Luc) reporter gene driven by Nrf2 binding antioxidant response elements (ARE) from the HO-1 gene in front of a minimal promoter (p44-HO-1Luc). In line with the protein half-life measurements, we found that hypoxia alone did not significantly affect Nrf2 activity. However, As(III) induced Nrf2 activity by about 8-fold under normoxia but only to about 5-fold under hypoxia (Fig. 5c). Together, these data suggest that Nrf2 could be involved in the As(III)-dependent regulation of HO-1 and likely HIF-1α.

We next asked whether a cross-talk between HIF-1α and Nrf2 exists. To test the possibility that Nrf2 could regulate HIF-1α expression, we used cells in which Nrf2 was depleted due to shRNA-mediated knockdown (Nrf2KD cells) and treated them with As(III) under normoxia and hypoxia. Similar to Nrf2 transcriptional activity, hypoxia had no effect on Nrf2 levels but As(III) strongly induced Nrf2 abundance under normoxia and hypoxia while these effects were greatly diminished in Nrf2KD cells (Fig. 5d, e).

Hypoxia and treatment with As(III) under normoxia induced HIF-1α by about 3-fold in the scrambled shRNA expressing control cells (Fig. 5d, e) as expected. Similarly, hypoxia induced HIF-1α levels also in Nrf2-depleted cells.
However, As(III) was not able to induce HIF-1α, neither under normoxia nor under hypoxia (Fig. 5d, e). Concomitantly, PAI-1 and HO-1 expression showed the same pattern (Fig. 5e). Together, these data show that Nrf2 contributes to the As(III)-dependent regulation of HIF-1α levels.

Role of ROS in As(III)-induced HIF-1α levels

The surprising involvement of the redox-sensitive transcription factor Nrf2 in the As(III)-dependent induction of HIF-1α raised the question whether alterations in the levels of ROS contribute to the As(III)-dependent HIF-1α induction. Indeed, As(III)-treated cells displayed an enhanced ROS formation (Fig. 6a).

NADPH oxidases (NOX) have a fundamental role in ROS generation, and in particular, NOX4 appears to be involved in stimulus-dependent ROS formation. Therefore, we investigated the possible involvement of NOX4 in the induction of ROS and the HIF-1α response to As(III). To do this, we used cells in which we depleted NOX4 by specific shRNA. The results demonstrate that NOX4 is involved in the induction of ROS in response to As(III) (Fig. 6a). In addition, and as shown earlier [27, 28], we found that NOX4 is induced by hypoxia. However, treatment of cells with As(III) induced NOX4 only under normoxia (Fig. 6c, d). In line, NOX4 depletion reduced HIF-1α induction in response to As(III). As expected and in agreement with earlier data [23], NOX4 depletion also reduced hypoxia-dependent HIF-1α induction while it did not affect HIF-1α levels under combined treatment (Fig. 6b, c). In order to address whether the NOX4 effects on HIF-1α are mediated at least in part by Nrf2, we examined Nrf2 activity along with HIF-1 activity upon depletion of NOX4. We found that knockdown of NOX4 reduced induction of HIF-1α activity by As(III) and hypoxia (Fig. 6d). Interestingly, depletion of NOX4 was without effect on the Nrf2 activity under hypoxia while it reduced the As(III)-mediated Nrf2 activity under normoxia to about the same levels as observed under hypoxia (Fig. 6d). Together, these data indicate that NOX4 is involved in the
As(III)-dependent regulation of HIF-1α by regulating Nrf2 activity.

It is well known that the ERK1/2 MAPK pathway and the PI3K/Akt pathway are major downstream mediators in the NOX signal chain in response to non-hypoxic stimuli [29]. Since As(III) appeared to act via NOX4, we further investigated whether the ERK1/2 and the PI3K/Akt pathways which are able to also activate Nrf2 [30] participate in the transduction of the As(III) effects. We found that As(III) treatment lead to phosphorylation of ERK1/2, and Akt; however, only depletion of NOX4 but not of NOX1 abolished ERK1/2 and Akt phosphorylation (Fig. 6e). No effects were noted under hypoxia (data not shown). In addition, we used specific inhibitors of the PI3K/Akt pathway and the ERK1/2 pathway and found that the PI3K inhibitor LY294002 abolished not only phosphorylation of Akt but also that of ERK1/2. By contrast, the MEK inhibitor U0126 only abolished the As(III)-dependent activation of ERK1/2 suggesting that phosphorylation of Akt is the upstream event necessary for the activation of ERK1/2 in response to As(III). In line, both inhibitors reduced the As(III)-induced increase in Nrf2 (Fig. 6f). Together, these data indicate that As(III) contributes to the regulation of HIF-1α via activation of NOX4, the PI3K/Akt and ERK1/2 pathway, and Nrf2.

As(III) induces proliferation, angiogenesis, and colony formation via HIF-1α and Nrf2

We next determined whether the As(III)/Nrf2-mediated HIF-1α regulation is involved in cell proliferation. To test this, we used cells in which Nrf2 or HIF-1α were knocked-down and measured the impact of As(III) on BrdU incorporation into newly synthesized DNA. We found that under normoxia, As(III) increased cell proliferation by about 30% in scrambled shRNA transfected control cells while Nrf2 or HIF-1α knockdown abolished the As(III) effect (Fig. 7a, b). By contrast, As(III) decreased cell proliferation under hypoxic conditions.
and knocking down HIF-1α or Nrf2 augmented these effects (Fig. 7a, b).

Since HIF-1α and Nrf2 are associated with the regulation of angiogenesis and tumor cell colony formation [31], we next tested whether As(III) affects capillary formation in endothelial cells and tumor colony growth of hepatoma cells in a HIF-1α or Nrf2-dependent manner using an in vitro matrigel assay and colony formation assay. Interestingly, As(III) increased both the formation of capillary-like structures and colonies under normoxic conditions. Knockdown of either Nrf2 or HIF-1α decreased formation of capillary-like structures as well as tumor cell colonies. By contrast, when capillary- and colony formation was assessed under hypoxia, it was found that As(III) reduced the hypoxia-dependent generation of capillary-like structures and colonies (Fig. 7c–f). Together, these data indicate that the regulation of HIF-1α and Nrf2 by As(III) contributes to the angiogenic responses of endothelial cells and the colony-forming properties of hepatoma cells.
Discussion

In this study, we identified a novel mechanism by which As(III) can induce HIF-1α and contribute to proliferation and angiogenesis. Thereby, As(III) exerts effects on HIF-1α via Nrf2-mediated enhancement of transcription which is connected to ROS generation involving NOX4, stimulation of the PI3/Akt and ERK1/2 pathways as well as by increasing the HIF-1α half-life.

Although previous reports showed that As(III) can act as inducer of HIF-1α [20, 32], those studies were only focusing on partial aspects of the participating signal chains. Our study confirms several mechanistic aspects but is the first identifying two novel participating entities, namely the NADPH oxidase NOX4 and the transcription factor Nrf2.

The generation of ROS in response to As(III) was already described earlier [33] and the current study confirmed this in the hepatoma cell line HepG2. However, this phenomenon is not restricted to hepatocyte-derived cells as in this study but was also reported to occur in various other cell types [34–36]. Furthermore, earlier findings suggested that a thiol-sensitive mechanism contributes to the As(III)-induced VEGF and HIF-1α expression in human ovarian cancer cells [18].

In line with these findings and the knowledge that HIF-1α can be regulated by ROS (reviewed in [37–39]), it was tempting to investigate whether the ROS were generated due to the action of NADPH oxidases. Earlier reports have given hints that NOX proteins contribute to arsenite-induced ROS production [40–43]. However, due to the use of non-selective
inhibitors like diphenyleneiodonium chloride (DPI) [44], it was so far not possible to identify the proper participating NOX member. The present study closes this gap; by using a specific knockdown approach, we were able to show that NOX4 is the predominant enzyme participating in As(III)-dependent ROS generation and HIF-1α induction. Our earlier findings [45, 46] and reports from other groups on ROS-dependent HIF-1α regulation [47–49] showed that the PI3K/Akt and the ERK1/2 MAPK pathways are of importance. Accordingly, we examined the involvement of both pathways and found that NOX4 acts upstream of the PI3K/Akt pathway and the ERK1/2 pathway, respectively. The latter findings are to some extent in line with earlier data reporting that activation of the Akt pathway contributes to the As(III)-increased HIF-1α level [20, 50, 51], though there was also a report which challenged the participation of the Akt pathway [44].

Although activation of ERK1/2 signaling was reported earlier to participate in the As(III)-mediated expression of angiogenesis-related factors and induction of HIF-1α [52, 53], our study is now first to show that the PI3K/Akt pathway and ERK1/2 pathways are interlinked and that the PI3K/Akt pathway acts upstream of ERK1/2.

In addition, we show for the first time that As(III) induced upregulation of HIF-1α mRNA under normoxia. The usage of cells with knockdown for the redox-sensitive transcription factor Nrf2 indicated that this factor plays a crucial role in the As(III)-dependent HIF-1α transcriptional regulation. Moreover, we showed that both Nrf2 and HIF-1α are participating in the As(III)-driven proliferation and angiogenic response. Indeed, similar links between HIF-1α and Nrf2 already appear to exist. For example, Nrf2 blockade seems to be of primary importance for tumors of the digestive tract. In particular, Nrf2 blockade suppressed colon tumor angiogenesis by inhibiting HIF-1α [54] and migration and invasion of esophageal squamous cell carcinoma cells in a hypoxic microenvironment [55]. In liver, it was found that Nrf2 contributes to ischemia-induced hepatocellular damage [56]. However, the action of the Nrf2 connection is not restricted to the digestive tract since knockdown of Nrf2 in glioma cells suppressed glioblastoma angiogenesis in vitro and in xenotransplanted mice by inhibiting HIF-1α [31, 57].

Vice versa, Nrf2 activation improved cell survival during hypoxia and hypoxia/reoxygenation in cardiomyoblasts [58], although in this study Nrf2 protein and activity were not induced by hypoxia.

Further, and in line with our study, the link between Nrf2 and NOX4 was also evident in cardiomyocytes [59]. However, the participation of NOX4 in the As(III) effects does not preclude that other NOX isoforms may also regulate the Nrf2-HIF-1α system. It is possible that, dependent on the cell-specific expression of the NOX proteins (for review, see [37]), other NOX isoforms may have similar effects. In that respect, an earlier study was able to show that the induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells augments HIF-1α signaling [60]. By contrast, also a feedback loop in which HIF-1 induction attenuates Nrf2-dependent gene expression appears to exist [61] indicating the complexity of the regulatory mechanism.

The connection between ROS, hypoxia, NOX4, Nrf2, and HIF-1α seems to play an important role in fibrosis where hypoxia is a major sign due to loss of endothelial cells, rarefaction of capillaries, and malperfusion. In line with that, it was found that NOX4-deficient mice exhibited attenuated angiogenesis [62] and targeting NOX4-Nrf2 could reverse persistent fibrosis in lungs of aging mice [63].

In addition to the transcriptional induction by As(III) under normoxia, we could also detect that As(III) downregulated the HIF-1α mRNA levels under hypoxia which subsequently explains the decreased HIF-1α protein levels in hypoxic As(III)-treated cells. This decrease is due to the lower activity of Nrf2 under hypoxia upon As(III) treatment and although the cells tried to counteract this decreased transcription by an increase in HIF-1α protein stability, a full compensation could not be reached. The stabilization of HIF-1α in response to As(III) is primarily achieved due to the action of ROS which inhibit the action of proline hydroxylases [23, 24] and similar findings were reported by another study showing that As(III) inhibits HIF-1α degradation via ROS at the level of proline hydroxylation [44]. In view of these findings, the current data support a model where, under normoxia, As(III) induces HIF-1α mRNA transcription, HIF-1α protein synthesis, HIF-1α target gene expression as well as cell proliferation and angiogenesis via NOX4 and the redox-sensitive transcription factor Nrf2 in conjunction with activation of PI3K/Akt and ERK1/2. Under hypoxia, As(III) does not induce NOX4 so that less ROS are formed with the consequence that HIF-1α can no longer be efficiently transcribed due to diminished Nrf2 activity. To overcome this deficit, cells prolong the half-life of HIF-1α; however, the transcriptional reduction appears to be only partially compensated with the net result that the overall HIF-1α protein levels are reduced with the consequence that cell proliferation and angiogenesis are strongly impaired. Overall, the current study is the first where As(III)-dependent effects were examined under normoxia and hypoxia and where different modes of HIF-1α transcription via Nrf2 have been identified (Fig. 8).

Although our findings with HepG2, Hep3B, and HMEC1 cells support the tumor growth-promoting role of As(III), additional studies will be required to determine whether other cancer cell types respond similarly to As(III) treatment. These findings can then also be seen in the context of therapeutic use. Since HIF-1α and tumor hypoxia are considered to be associated with tumor progression [64], it would be beneficial to downregulate HIF-1α under hypoxic conditions as seen in the current study. Indeed, these findings may help to explain why arsenic is of therapeutic use; it gained a renaissance based on recent
the anti-carcinogenic actions of As(III). It aims to further foster knowledge to better understand the pro-carcinogenic mechanisms associated with diseases like cancer as well as having profound effects on cell growth and angiogenesis. The cells try to compensate against this inhibitory effect on HIF-1α transcription by prolonging its protein half-life, cell proliferation and angiogenesis are strongly impaired.

reports from China describing that a traditional Chinese medicine, “Ai-ling 1,” in which arsenic is the active ingredient, can be used to successfully treat patients with acute promyelocytic leukemia (APL) [65–67]. A number of clinical trials using arsenic to treat patients with APL confirmed the beneficiary effects [68, 69] with the consequence that arsenic has been approved as a standard therapy for the treatment of patients with relapsed or refractory APL in the USA and Europe [70] EU/1/02/204/001; http://ec.europa.eu/enterprise/pharmaceuticals/orphanmp/index.htm.

Overall, these findings and the results of the present study indicate that As(III) has an ambivalent mode of action with having profound effects on cell growth and angiogenesis which are associated with diseases like cancer as well as having use as therapeutic agent. The current study adds new knowledge to better understand the pro-carcinogenic mechanisms of As(III), and at the same time it aims to further foster the discussion and research to unravel the mechanisms behind the anti-carcinogenic actions of As(III).

Acknowledgments Work of the authors is supported by grants from the Biocenter Oulu, the Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation, Academy of Finland, and by the European Cooperation in Science and Technology (COST Action BM1203/EU-ROS).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. The World Bank (2005) Towards a more effective operational response. The World Bank, Washington, DC
2. Tseng CH, Chong CK, Tseng CP, Hsueh YM, Chiou HY, Tseng CC, Chen CJ (2003) Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol Lett 137:15–21
3. Feldman RG, Niles CA, Kelly-Hayes M, Sax DS, Dixon WJ, Thompson DJ, Landau E (1979) Peripheral neuropathy in arsenic smelter workers. Neurology 29:939–944
4. Wasserman GA, Liu X, Parvez F, Ahsan H, Factor-Litvak P, van Geen A, Slavkovich V, Lolacono NJ, Cheng Z, Hussain I et al (2004) Water arsenic exposure and children’s intellectual function in Araihazar, Bangladesh. Environ Health Perspect 112:1329–1333
5. Arsenic and arsenic compounds (1980). IARC Monogr Eval Carcinog Risk Chem Hum 23:39–141
6. Chiou HY, Huang WL, Su CL, Chang SF, Hsu YH, Chen CJ (1997) Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke 28:1717–1723
7. Semenza GL (2014) Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol 76:39–56
8. Masson N, Ratcliffe PJ (2014) Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab 2:3-002-2-3.
9. Losman JA, Kaelin WG Jr (2013) What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 27:836–852
10. Flugel D, Gorlach A, Michiels C, Kietzmann T (2007) Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 27:3253–3265
11. Flugel D, Gorlach A, Kietzmann T (2012) GSK-3beta regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1alpha. Blood 119:1292–1301
12. Mylonis I, Chachami G, Samiotaki M, Panayotaki G, Paraseva E, Kalousi A, Georgatsou E, Bonanou S, Simos G (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281:33095–33106
13. Gorlach A (2009) Regulation of HIF-1alpha at the transcriptional level. Curr Pharm Des 15:3844–3852
14. Gorlach A, Klappa P, Kietzmann T (2006) The endoplasmic reticulum: folding, calcium homeostasis, signaling, and redox control. Antioxid Redox Signal 8:1391–1418
15. Kietzmann T, Gorlach A (2005) Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin Cell Dev Biol 16:474–486
50. Liu LZ, Jiang Y, Carpenter RL, Jing Y, Peiper SC, Jiang BH (2011) Role and mechanism of arsenic in regulating angiogenesis. PLoS One 6:e20858
51. Wang Y, Wei Y, Zhang H, Shi Y, Li Y, Li R (2012) Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase. Med Oncol 29:1328–1334
52. Wang F, Liu S, Xi S, Yan L, Wang H, Song Y, Sun G (2013) Arsenic induces the expressions of angiogenesis-related factors through PI3K and MAPK pathways in SV-HUC-1 human uroepithelial cells. Toxicol Lett 222:303–311
53. Xu Y, Li Y, Li H, Pang Y, Zhao Y, Jiang R, Shen L, Zhou J, Wang X, Liu Q (2013) The accumulations of HIF-1alpha and HIF-2alpha by JNK and ERK are involved in biphasic effects induced by different levels of arsenite in human bronchial epithelial cells. Toxicol Appl Pharmacol 266:187–197
54. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y, Kwak MK (2011) NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res 71:2260–2275
55. Shen H, Yang Y, Xia S, Rao B, Zhang J, Wang J (2014) Blockage of NRF2 suppresses the migration and invasion of esophageal squamous cell carcinoma cells in hypoxic microenvironment. Dis Esophagus 27:685–692
56. Ke B, Shen XD, Zhang Y, Ji H, Gao F, Yue S, Kamo N, Zhai Y, Yamamoto M, Busuttil RW et al (2013) KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J Hepatol 59:1200–1207
57. Ji X, Wang H, Zhu J, Zhu L, Pan H, Li W, Zhou Y, Gong Z, Yan F, Chen S (2014) Blockage of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Int J Cancer 135:574–584
58. Kolamunne RT, Dias IH, Vernallis AB, Grant MM, Griffiths HR (2013) Nrf2 activation supports cell survival during hypoxia and hypoxia/reoxygenation in cardiomyoblasts; the roles of reactive oxygen and nitrogen species. Redox Biol 1:418–426
59. Brewer AC, Mural TV, Arno M, Zhang M, Anilkumar NP, Mann GE, Shah AM (2011) Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med 51:205–215
60. Malec V, Gottschald OR, Li S, Rose F, Seeger W, Hanze J (2010) HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic Biol Med 48:1626–1635
61. Loboda A, Stachurska A, Florczyk U, Rudnicka D, Jazwa A, Wegrzyn J, Kozakowska M, Stalinska K, Poellinger L, Levenon AL et al (2009) HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells. Antioxid Redox Signal 11:1501–1517
62. Schroder K, Zhang M, Benkhoﬀ S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luethke P, Michaelis UR, Weissmann N et al (2012) Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110:1217–1225
63. Hecker L, Logsdon NJ, Kurundkar D, Kurundkar A, Bemard K, Hock T, Meldrum E, Sanders YY, Thanmickal JV (2014) Reversal of persistent ﬁbrosis in aging by targeting Nox4-Nrf2 redox imbalance. Sci Transl Med 6:231ra47
64. Semenza GL (2014) Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol 9:47–71
65. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ et al (1996) Pharmacokinetics and efﬁcacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia (APL): I. Clinical efﬁcacy and pharmacokinetics in relapsed patients. Blood 89:3354–3360
66. Chen GQ, Shen ZX, Wu F, Han JY, Miao JM, Zhong HJ, Li XS, Zhao JQ, Zhu J, Fang ZW et al (1996) Pharmacokinetics and efﬁcacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 10:825–828
67. Wang G, Li W, Cui J, Gao S, Yao C, Jiang Z, Song Y, Yuan CJ, Yang Y, Liu Z et al (2004) An efﬁcient therapeutic approach to patients with acute promyelocytic leukemia using a combination of arsenic trioxide with low-dose all-trans retinoic acid. Hematol Oncol 22:63–71
68. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabriole J, Scheinberg DA et al (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341–1348
69. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P et al (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852–3860
70. National Comprehensive Cancer Network (2003) Acute myeloid leukemia. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 1:520–539